Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues.
about
Adverse safety events in patients with Chronic Kidney Disease (CKD).Association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use prior to major elective surgery and the risk of acute dialysisHypertensive nephropathy: prevention and treatment recommendations.Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction.The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney DiseaseEvidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes.The frequency of hyperkalemia and its significance in chronic kidney disease.Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study.New therapeutic strategies with combined renin-angiotensin system inhibitors for pediatric nephropathy.Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression.Safety, tolerability, and efficacy of azilsartan medoxomil with or without chlorthalidone during and after 8 months of treatment for hypertensionEarly pancreas graft failure is associated with inferior late clinical outcomes after simultaneous kidney-pancreas transplantation.Role of single-pill combination therapy in optimizing blood pressure control in high-risk hypertension patients and management of treatment-related adverse events.Optimal medical management in patients with renovascular hypertension.Renal Targeted Therapies of Antihypertensive and Cardiovascular Drugs for Patients With Stages 3 Through 5d Kidney Disease.Antiproteinuric effect of angiotensin-converting enzyme inhibitors and an angiotensin II receptor blocker in patients with lupus nephritis.Comparison of long-term safety of fixed-dose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide.
P2860
Q30245199-C5C75576-5281-427C-8C28-312C246BEB9FQ33613082-9E8C646E-7E44-4DC9-A889-B00EB5246EF2Q34131899-851439B0-E64C-495A-B075-A09E46419898Q35407690-29560A02-2202-48DC-A7C4-03D24CA7089DQ35914820-1D608531-E88D-4F35-B94C-538943A7DD6CQ36384453-9F56B90F-98BF-4CFD-8A66-18954B83FC36Q36530203-661B6069-4AEC-487C-AA1D-6BEB8C685379Q36762587-73835CDB-6BEF-4D2C-8208-04FFD02C9308Q37043556-636EF802-40B0-419D-A40F-67B479A54077Q37158325-34BE726B-2E8E-47BA-B9CD-53FD3FE65B39Q37257463-76DC52B2-4F99-44EA-B2FA-642EDD36F51DQ37318279-DFB9E334-8D52-45F1-AE77-C0B9598EE800Q38048939-95D968E6-0A1C-424B-8D02-9EF18AD8FDD6Q38089693-2DBFE6E7-0163-46B1-B5E1-D7C0238752FBQ38739039-525D7F63-AC10-45DD-AF7E-CF3B66E06C2CQ45934007-0C79F1F9-5C8E-4BC4-862E-7029B41744A1Q46669579-E80490EB-7FF2-4328-B2DB-9970F631A557
P2860
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Angiotensin-converting enzyme ...... renal disease: safety issues.
@ast
Angiotensin-converting enzyme ...... renal disease: safety issues.
@en
type
label
Angiotensin-converting enzyme ...... renal disease: safety issues.
@ast
Angiotensin-converting enzyme ...... renal disease: safety issues.
@en
prefLabel
Angiotensin-converting enzyme ...... renal disease: safety issues.
@ast
Angiotensin-converting enzyme ...... renal disease: safety issues.
@en
P1476
Angiotensin-converting enzyme ...... renal disease: safety issues.
@en
P2093
Amy J Mangrum
George L Bakris
P304
P356
10.1016/J.SEMNEPHROL.2003.11.001
P577
2004-03-01T00:00:00Z